Allied Market Research
Loading...
0
New
New
2022
Advanced Drug Delivery Market

Advanced Drug Delivery Market by Product Type (Drug Eluting Lens, Microneedle Patch, Hydrogel Drug Delivery and Nano Carrier) and End User (Hospitals, Specialized Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

A14784
Pages: 190
Dec 2021 | 395 Views
   
Author(s) : Shraddha Mali, Madhuvanti Divekar , Onkar Sumant
Tables: 92
Charts: 32
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Advanced Drug Delivery Market

Request Now !

Advanced Drug Delivery Market Statistics 2030:

The global advanced drug delivery market size was valued at $44,029.59 million in 2020, and is projected to reach $1,95,132.45 million by 2030, registering a CAGR of 16.0% from 2021 to 2030. The term "advanced drug delivery" refers to the methods, formulations, and processes (routes of administration) used to provide drugs for a variety of uses or therapeutic purposes. Advanced drug delivery is a more controlled means of delivering the drug molecule to the targeted site. Advance drug delivery refers to drug delivery systems that are based on novel drug delivery strategies and make use of cutting-edge technologies. They are designed to deliver drugs in a controlled or modulated way within the tissue or cells, resulting in safe and effective therapy.

The phrase advanced drug delivery (ADD) refers to technologies that control the pace at which drugs are released. The kind of disease, drug, and desired result all have a significant impact on the technology used. The goal of an advanced drug delivery system is to deliver a therapeutic amount of medicine to the specific site in the body as rapidly and effectively as possible in order to achieve and then maintain the target drug concentration. 

Global-Advanced-Drug-Delivery-Market

Get more information on this report : Request Sample Pages

The ability to deliver a drug more selectively to a specific site; easier, more accurate, less frequent dosing; decreased variability in systemic drug concentrations; absorption that is more consistent with the site and mechanism of action; and reductions in toxic metabolites are all advantages of advanced drug delivery systems over traditional systems. The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems

Increasing incidences of chronic diseases in overall population is one of the major factors that drives the market. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both. Furthermore, considerable rise in healthcare expenditure worldwide has boosted the advanced drug delivery market. The major factors that are responsible for the increase in healthcare expenditure are rise in population especially geriatric, rise in chronic diseases and increased medical service utilization. Surge in healthcare spending has further grown due to the consumer awareness for health, rise in initiatives taken by the government, companies and increase in investment by public-private sector companies for the unmet demand in developing and under-developed countries. Thus, all these factors collectively provide opportunity for investments in R & D activities for the development of advanced drug delivery solutions for better drug efficacy and safe therapy for already existing drugs as well as upcoming new molecular entities, which further drives the growth of the market.

Exponential rise in overall population has led to surge in prevalence of chronic diseases as well as emergence of new diseases. This has further increased R&D activities to introduce new drug molecules. Technological advancements have been made to develop advanced drug delivery system by improving pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy of the compounds by designing various advanced drug delivery routes. Moreover, rise in funding’s & investments by the government, product launches, collaborations for development of advanced drug delivery systems by the key players of the market is expected to significantly boost the growth of the market in the forecast period. However, the considerable rise in number of drug recalls and drug failures is expected to impede the advanced drug delivery market growth. 

Impact Of Covid-19 On Advanced Drug Delivery Market (Pre And Post Analysis)

In addition, the COVID-19 outbreak is anticipated to have a positive impact on the growth of the global advanced drug delivery market. A large number of clinics and hospitals throughout the world were reorganized to boost hospital capacity for COVID-19 patients. Due to the rapidly increasing COVID-19 cases, the non-essential processes faced a possible backlog. Furthermore, the lockdown hampered manufacturing and transportation of crucial hospital supplies. Conversely, research studies and activities, including clinical trials for the efficacy and safety, for the treatment of COVID-19 immunization by various researchers, companies, and government boosted the advanced drug delivery market. 

Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in drug delivery is an emerging opportunity for key players to invest in the advanced drug delivery market.

Advanced Drug Delivery Market Segmentation

The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others. 

Region wise, the advanced drug delivery market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).

Advanced Drug Delivery Market
By Product Type

Your browser does not support the canvas element.

Nano Carrier holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review

Depending on the product type, the nano carrier segment dominated the market in 2020, and is expected to continue this trend during the forecast period, due to increased availability of drug, decreased active drug degradation, lower toxicity and effective targeted therapy.

By end user, the specialized clinics segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.

North America accounted for a majority of the global advanced drug delivery market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in adoption of advanced technologies, owing to the better adoption of improved drug delivery solutions, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, rise in diseases prevalence and increase in investments in the healthcare sector in the region.

The key players operating in the global advanced drug delivery market are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.

Advanced Drug Delivery Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 17.9% during the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the advanced drug delivery market, and the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing advanced drug delivery market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the advanced drug delivery market.

Key Market Segments

  • By Product Type
    • Drug eluting lens
    • Microneedle patch
    • Hydrogel drug delivery
    • Nano carrier
  • By End User
    • Hospitals
    • Specialized clinics
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA
  • KEY MARKET PLAYERS
    • Alnylam Pharmaceuticals Inc.
    • Altaris Capital Partners Llc. (Kindeva Drug Delivery)
    • Bausch Health Companies Inc., (Bausch & Lomb)
    • Biogen Limited
    • Endo International Plc.
    • Johnson & Johnson (Johnson & Johnson Vision)
    • Micropoint Technologies
    • Novo Nordisk A/S
    • Ocular Therapeutix Inc.
    • Takeda Pharmaceutical Company Limited
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of chronic disorders that require the use of drug delivery systems
3.5.1.2.Surge in healthcare expenditure worldwide
3.5.1.3.Technological advancements and developments made by key players in drug delivery system market

3.5.2.Restraint

3.5.2.1.Rise in number of drug recalls and drug failures

3.5.3.Opportunity

3.5.3.1.Lucrative opportunities in emerging markets

3.6.Impact analysis
3.7.Impact analysis of COVID-19 on the advanced drug delivery market
3.8.Patent analysis, 2019-2021

3.8.1.Patent analysis, by world
3.8.2.Patent analysis, by year

3.9.Clinical trials analysis, 2019-2021

CHAPTER 4:ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Drug eluting lens

4.2.1.Key market trends, growth factors, and opportunities

4.3.Microneedle patch

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Hydrogel drug delivery

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Nano carrier

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:ADVANCED DRUG DELIVERY MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Specialized clinics

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Others

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:ADVANCED DRUG DELIVERY MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America advanced drug delivery market, by product type
6.2.3.North America advanced drug delivery market, by end user
6.2.4.Market size and forecast, by country

6.2.4.1.U.S.

6.2.4.1.1.U.S. advanced drug delivery market, by product type
6.2.4.1.2.U.S. advanced drug delivery market, by end user

6.2.4.2.Canada

6.2.4.2.1.Canada advanced drug delivery market, by product type
6.2.4.2.2.Canada advanced drug delivery market, by end user

6.2.4.3.Mexico

6.2.4.3.1.Mexico advanced drug delivery market, by product type
6.2.4.3.2.Mexico advanced drug delivery market, by end user

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe advanced drug delivery market, by product type
6.3.3.Europe advanced drug delivery market, by end user
6.3.4.Market size and forecast, by country

6.3.4.1.Germany

6.3.4.1.1.Germany advanced drug delivery market, by product type
6.3.4.1.2.Germany advanced drug delivery market, by end user

6.3.4.2.France

6.3.4.2.1.France advanced drug delivery market, by product type
6.3.4.2.2.France advanced drug delivery market, by end user

6.3.4.3.UK

6.3.4.3.1.UK advanced drug delivery market, by product type
6.3.4.3.2.UK advanced drug delivery market, by end user

6.3.4.4.Italy

6.3.4.4.1.Italy advanced drug delivery market, by product type
6.3.4.4.2.Italy advanced drug delivery market, by end user

6.3.4.5.Spain

6.3.4.5.1.Spain advanced drug delivery market, by product type
6.3.4.5.2.Spain advanced drug delivery market, by end user

6.3.4.6.Rest of Europe

6.3.4.6.1.Rest of Europe advanced drug delivery market, by product type
6.3.4.6.2.Rest of Europe advanced drug delivery market, by end user

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific advanced drug delivery market, by product type
6.4.3.Asia-Pacific advanced drug delivery market, by end user
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Japan advanced drug delivery market, by product type
6.4.4.1.2.Japan advanced drug delivery market, by end user

6.4.4.2.China

6.4.4.2.1.China advanced drug delivery market, by product type
6.4.4.2.2.China advanced drug delivery market, by end user

6.4.4.3.Australia

6.4.4.3.1.Australia advanced drug delivery market, by product type
6.4.4.3.2.Australia advanced drug delivery market, by end user

6.4.4.4.India

6.4.4.4.1.India advanced drug delivery market, by product type
6.4.4.4.2.India advanced drug delivery market, by end user

6.4.4.5.South Korea

6.4.4.5.1.South Korea advanced drug delivery market, by product type
6.4.4.5.2.South Korea advanced drug delivery market, by end user

6.4.4.6.Rest of Asia-Pacific

6.4.4.6.1.Rest of Asia-Pacific advanced drug delivery market, by product type
6.4.4.6.2.Rest of Asia-Pacific advanced drug delivery market, by end user

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA advanced drug delivery market, by product type
6.5.3.LAMEA advanced drug delivery market, by end user
6.5.4.LAMEA advanced drug delivery market, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil advanced drug delivery market, by product type
6.5.4.1.2.Brazil advanced drug delivery market, by end user

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia advanced drug delivery market, by product type
6.5.4.2.2.Saudi Arabia advanced drug delivery market, by end user

6.5.4.3.South Africa

6.5.4.3.1.South Africa advanced drug delivery market, by product type
6.5.4.3.2.South Africa advanced drug delivery market, by end user

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA advanced drug delivery market, by product type
6.5.4.4.2.Rest of LAMEA advanced drug delivery market, by end user

CHAPTER 7:COMPANY PROFILES

7.1.ALNYLAM PHARMACEUTICALS, INC.

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.ALTARIS CAPITAL PARTNERS, LLC. (KINDEVA DRUG DELIVERY)

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio

7.3.BAUSCH HEALTH COMPANIES INC. (BAUSCH & LOMB)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.BIOGEN LIMITED

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments

7.5.ENDO INTERNATIONAL PLC.

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.JOHNSON & JOHNSON (JOHNSON & JOHNSON VISION)

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MICROPOINT TECHNOLOGIES PTE LTD.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio

7.8.NOVO NORDISK

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.OCULAR THERAPEUTIX, INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments

7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1.Company overview
7.10.2.Operating business segments
7.10.3.Product portfolio
7.10.4.Business performance

LIST OF TABLES

TABLE 01.ADVANCED DRUG DELIVERY MARKET, BY CLINICAL TRIALS
TABLE 02.ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 03.ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY REGION, 2020-2030 ($MILLION)
TABLE 04.ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY REGION, 2020-2030 ($MILLION)
TABLE 06.ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 07.ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2020–2030 ($MILLION)
TABLE 08.ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY REGION, 2020–2030($MILLION)
TABLE 09.ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2020–2030($MILLION)
TABLE 10.ADVANCED DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 12.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 13.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 14.U.S. ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 15.U.S. ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 16.CANADA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 17.CANADA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 18.MEXICO ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 19.MEXICO ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 20.EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 21.EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 22.EUROPE ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 23.GERMANY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 24.GERMANY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 25.FRANCE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 26.FRANCE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27.UK ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 28.UK ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 29.ITALY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 30.ITALY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31.SPAIN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 32.SPAIN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 33.REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 34.REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 35.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 36.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 38.JAPAN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 39.JAPAN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40.CHINA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 41.CHINA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 42.AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 43.AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44.INDIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 45.INDIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46.SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 47.SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50.LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 51.LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 52.LAMEA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53.BRAZIL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 54.BRAZIL ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 55.SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 56.SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 57.SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 58.SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59.REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 60.REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 61.ALNYLAM: COMPANY SNAPSHOT
TABLE 62.ALNYLAM: OPERATING BUSINESS SEGMENTS
TABLE 63.ALNYLAM: PRODUCT PORTFOLIO
TABLE 64.ALNYLAM: KEY DEVELOPMENTS
TABLE 65.ALTARIS: COMPANY SNAPSHOT
TABLE 66.ALTARIS: OPERATING SEGMENTS
TABLE 67.ALTARIS HEALTHCARE: PRODUCT PORTFOLIO
TABLE 68.BAUSCH: COMPANY SNAPSHOT
TABLE 69.BAUSCH: OPERATING SEGMENTS
TABLE 70.BAUSCH: PRODUCT PORTFOLIO
TABLE 71.BIOGEN: COMPANY SNAPSHOT
TABLE 72.BIOGEN: OPERATING SEGMENTS
TABLE 73.BIOGEN: PRODUCT PORTFOLIO
TABLE 74.BIOGEN: KEY DEVELOPMENTS
TABLE 75.ENDO: COMPANY SNAPSHOT
TABLE 76.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 77.ENDO: PRODUCT PORTFOLIO
TABLE 78.JOHNSON: COMPANY SNAPSHOT
TABLE 79.JOHNSON: PRODUCT SEGMENTS
TABLE 80.JOHNSON: PRODUCT PORTFOLIO
TABLE 81.JOHNSON: KEY DEVELOPMENTS
TABLE 82.MICROPOINT: SNAPSHOT
TABLE 83.MICROPOINT: OPERATING SEGMENT
TABLE 84.MICROPOINT: PRODUCT PORTFOLIO
TABLE 85.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 86.NOVO NORDISK: OPERATING SEGMENTS
TABLE 87.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 88.BIOGEN: KEY DEVELOPMENTS
TABLE 89.OCULAR THERAPEUTIX: COMPANY SNAPSHOT
TABLE 90.OCULAR THERAPEUTIX: OPERATING SEGMENTS
TABLE 91.OCULAR THERAPEUTIX: PRODUCT PORTFOLIO
TABLE 92.OCULAR THERAPEUTIX: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL ADVANCED DRUG DELIVERY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.PATENTS REGISTERED/APPROVED IN THE WORLD, 2019-2021
FIGURE 14.PATENTS ANALYSIS, BY YEAR, 2019–2021
FIGURE 15.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY COUNTRY, 2020-2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY, BY COUNTRY, 2020-2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY COUNTRY,  2020-2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY,  2020-2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY COUNTRY, 2020-2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 21.ALNYLAM: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.BAUSCH: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.BAUSCH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24.BAUSCH: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ENDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.ENDO: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 28.JOHNSON: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.JOHNSON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31.NET SALES, 2018–2020 ($MILLION)
FIGURE 32.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)

 
 

This section provides the opinions of the top level CXOs in the global advanced drug delivery market. According to the insights of CXOs, increase in prevalence of chronic diseases, emergence of novel diseases due to genetic mutations, surge in targeted drug delivery and technological advancements are expected to significantly boost the growth of the advanced drug delivery market.

The CXOs further added that rise in drug discovery & development, introduction of novel drugs for the treatment of emerging new diseases, personalization of treatments, advanced formulations and the use of novel drug carriers have been shown to improve the efficiency and efficacy of drug delivery systems, leading to better treatment outcomes. Furthermore, advancement in designing the drug delivery systems for the available drugs by overcoming the limitation related to factors such as adsorption, solubility, toxicity, molecular weight, metabolism, distribution and excretion, notably contributes toward the market growth.

Moreover, the development of improved drug delivery techniques is now preferred before the discovery of novel compounds, due to stringent government regulations. There are several dosage forms into which a drug substance can be incorporated for effective delivery through oral, parenteral, pulmonary, transdermal, transmucosal and other carrier based drug delivery system. Biotechnology and nanotechnology advancements have considerably accelerated the development of innovative drug delivery techniques.

The market gains interest of healthcare companies, owing to surge in R&D and increase in focus in adoption of advanced drug delivery for safe and effective therapy.

North America is expected to witness highest growth, in terms of revenue, owing to rapidly growing geriatric population, robust R&D infrastructure for life science researches, rapid adoption of adoption of advanced technologies, improved drug delivery solutions, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, due to the continuous government support for pharmaceutical and biotechnology R&D, increase in public–private investments, and rise in number of research activities in the healthcare sector for improved and efficient drug delivery.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of advanced drug delivery market is $44,029.59 million in 2020.

A. The forecast period for advanced drug delivery market is 2021 to 2030

A. The market value of advanced drug delivery market in 2021 is $51,183.67million.

A. The base year is 2020 in advanced drug delivery market

A. Top companies such as Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited held a high market position in 2020.

A. Nano carrier segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to their increased drug availability, reduced active drug degradation and further technological advancements is expected to drive the segment

A. Increase in prevalence of chronic diseases, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.

A. North America is projected to account for a major share of the global advanced drug delivery market during the forecast period. Asia-Pacific is projected to offer lucrative oppurtunities due to increase in prevalence of chronic diseases, rise in investments for drug discovery in the R & D sector due to presence of key players across the region.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Advanced Drug Delivery Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers